Biogen to Acquire Reata Pharmaceuticals

Many of you will have seen the news from last weekend announcing that Biogen has entered an agreement for the proposed acquisition of Reata Pharmaceuticals.

The impact of this on the plans for the distribution of SKYCLARYS both in the US and internationally are of particular interest to everyone in our community.

Right up until this week, we have been in ongoing discussions with Reata and along with FARA in the United States, have now expanded our focus to the Biogen team.

Whilst at this early stage we are unsure of the impact of the acquisition, we are encouraged by statements from Biogen that they recognise opportunities for geographic expansion in Latin America, Middle East and Australia / New Zealand.

In a letter to the FA Community, Reata commented that the acquisition has the foundation in place to accelerate the delivery of SKYCLARYS® to patients around the world.

We will continue to keep you updated on our discussions as news emerges.